Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P08908 (
5-HT1A
)
5,574
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We assessed whether repeated arsenic exposure can decrease paracetamol-mediated antinociception by modulating serotonergic and endocannabinoid pathways. Rats were preexposed to elemental arsenic (4ppm) as sodium arsenite through drinking water for 28 days. Next day paracetamol's (400mg/kg, oral) antinociceptive activity was assessed through formalin-induced nociception. Serotonin content and gene expression of
5-HT1A
, 5-HT2A and CB1 receptors were evaluated in brainstem and frontal cortex.
Arsenic
decreased paracetamol-mediated analgesia. Paracetamol, but not arsenic, increased serotonin content in these regions.
Arsenic
attenuated paracetamol-mediated increase in serotonin level. Paracetamol did not alter
5-HT1A
expression, but caused down-regulation of 5-HT2A and up-regulation of CB1 receptors.
Arsenic
down-regulated these receptors. However, paracetamol-mediated down-regulation of 5-HT2A was more pronounced.
Arsenic
did not modify paracetamol's effect on
5-HT1A
expression, but reduced paracetamol-mediated down-regulation of 5-HT2A and reversed up-regulation of CB1 receptors. Results suggest arsenic reduced paracetamol-induced analgesia possibly by interfering with pronociceptive 5-HT2A and antinociceptive CB1 receptors.
...
PMID:Arsenic decreases antinociceptive activity of paracetamol: possible involvement of serotonergic and endocannabinoid receptors. 2512 69